Quebec-based Medicago plans to begin a 30,000 participant late-stage trial of its plant-based COVID-19 vaccine. It is being made with a booster from GlaxoSmithKline. In a phase 1 trial, 100% of participants developed antibodies with no severe adverse effects. The vaccine also offers the benefit of being able to be safely stored between 2-8 degrees Celsius, a significant logistical advantage over some that are currently in use.